Dr. Iyengar is a Dorothy H. and Lewis Rosenstiel Professor in the Department of Pharmacology and Systems Therapeutics and the Director and Principal Investigator of the NIGMS funded Systems Biology Center New York.
Trained as a biochemist, Dr. Iyengar's research focuses on cell signaling networks with emphasis on heterotrimeric G protein pathways. His laboratory uses a combination of experimental and computational approaches to understand the regulatory and information processing capabilities of cellular signaling networks.
Systems pharmacology and systems biology
Computational cell biology
Cellular signaling networks
Spatial modeling of cell signaling
G-protein mediated intracellular signaling in neurons
Spatiotemporal organization of cellular networks
In the News:
GLP-1, TZD Combo May Cut Heart Risk
Big Data Reaps Big Rewards in Drug Safety
Can 'Big Data' Help Increase Drug Safety?
Mount Sinai School of Medicine Bringing Free Courses Online
Mount Sinai Discovers Genetic Framework to Explain and Predict Adverse Drug Reactions
Addiction, Axonal Growth and Degeneration, Bioinformatics, Cell Adhesion, Cell Biology, Cell Motility, Cell Transformation, Computational Biology, Computer Simulation, Cytoskeleton, Dendritic Cells, Drug Design and Discovery, Hippocampus, Mathematical Modeling of Biomedical Systems, Mathematical and Computational Biology, Membranes, Memory, Nanotechnology, Phosphorylation, Protein Kinases, Protein Phosphatases, Proteomics, Receptors, Signal Transduction, Synaptic Plasticity, Systems Biology, Theoretical Biology, Transcription Factors, cAMP
Biophysics and Systems Pharmacology [BSP], Neuroscience [NEU]
BS, Bombay University
MSc, Bombay University
MS, University of Houston
PhD, University of Houston
Fellowship, Baylor College of Medicine
Summary of Research
The Iyengar laboratory is interested in understanding how signals are routed and processed through cellular signaling networks including mechanisms of information sorting and integration.
We are interested in understanding dynamics of network topology. For this we focus on identifying regulatory motifs such as feedback and feedforward loops and determining their information processing capability. We have constructed and analyzed dynamic maps of these motifs to understand how cellular signaling networks engage the various cellular machinery to produce physiological responses to extra-cellular signals. To study complex cell signaling networks we utilize a combination of experimental and theoretical approaches. Multidimensional experimental approaches currently being used in the laboratory include reverse-phase phosphoproteomic arrays, transcription factor arrays, ChIP-Seq and mRNA profiling by sequencing. These experimental approaches are being integrated with theoretical analysis using both graph theory approaches and differential equation based modeling to understand network regulation of cell proliferation and activity induced synaptic plasticity.
We are interested in understanding how spatial organization within cells and tissues contributes to dynamic stability. We are studying the role of cell shape in regulating information processing within signaling networks. For these studies at the experimental level we are using approaches to observe and quantify biochemical signaling reactions in live cells. We are also using patterned surfaces at the nano and microscale as to obtain cells of specific shapes that can be imaged. To decipher the information content in cell shape we are analyzing signaling networks using partial differential equations. We are developing spatially realistic models of signaling networks to understand the origins and dynamics of microdomains of signaling components. We are also interested in understanding the dynamics underlying tissue integrity. We are developing multi-scale models as well as experimentally engineered systems to determine if a dynamic loop that integrates signaling networks in multiple cell types forms the basis for tissue integrity.
We are developing systems level approaches to understanding drug action at a genome-wide level. We are constructing large scale networks to capture all of the known protein-protein interactions in the human genome to computationally identify selective regions (disease neighborhood) within the interaction space associated with specific diseases. We are analyzing the relationship between drug targets and other cellular components to understand the relationship between disease neighborhood and targets of drugs used to treat the disease. From such analyses we are attempting to predict adverse events and explain adverse events reports in the FDA–AERS database.
For more information, please visit the Iyengar Laboratory, Systems Pharmacology and Systems Biology website.
Azeloglu EU, Hardy SV, Eungdamrong NJ, Chen Y, Jayaraman G, Chuang PY, Fang W, Xiong H, Neves SR, Jain MR, Li H, Ma'ayan A, Gordon RE, He JC, Iyengar R. Interconnected network motifs control podocyte morphology and kidney function. Science Signaling 2014; 7(311).
Zhao S, Nishimura T, Chen Y, Azeloglu EU, Gottesman O, Giannarelli C, Zafar MU, Benard L, Badimon JJ, Hajjar RJ, Goldfarb J, Iyengar R. Systems Pharmacology of Adverse Event Mitigation by Drug Combinations. Science Translational Medicine 2013 Oct; 5(206).
Rangamani P, Lipshtat A, Azeloglu EU, Calizo RC, Hu M, Ghassemi S, Hone J, Scarlata S, Neves SR, Iyengar R. Decoding information in cell shape. Cell 2013 Sep; 154(6).
Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Science Translational Medicine 2012 Mar; 4(126).
Rangamani P, Fardin MA, Xiong Y, Lipshtat A, Rossier O, Sheetz MP, Iyengar R. Signaling network triggers and membrane physical properties control the actin cytoskeleton-driven isotropic phase of cell spreading. Biophysical Journal 2011 Feb; 100(4): 845-857.
Xiong Y, Rangamani P, Fardin MA, Lipshtat A, Dubin-Thaler B, Rossier O, Sheetz MP, Iyengar R. Mechanisms controlling cell size and shape during isotropic cell spreading. Biophysical Journal 2010 May; 98(10): 2136-2146.
Berger SI, Ma'Ayan A, Iyengar R. Systems pharmacology of arrhythmias. Science Signaling 2010 Apr; 3(118): ra30.
Lipshtat A, Jayaraman G, He JC, Iyengar R. Design of versatile biochemical switches that respond to amplitude, duration, and spatial cues. Proc Natl Acad Sci U S A 2010 Jan; 107(3): 1247-1252.
Ma'ayan A, Cecchi GA, Wagner J, Rao AR, Iyengar R, Stolovitzky G. Ordered cyclic motifs contribute to dynamic stability in biological and engineered networks. Proc Natl Acad Sci U S A 2008 Dec; 105(49): 19235-19240.
Neves SR, Tsokas P, Sarkar A, Grace EA, Rangamani P, Taubenfeld SM, Alberini CM, Schaff JC, Blitzer RD, Moraru II, Iyengar R. Cell shape and negative links in regulatory motifs together control spatial information flow in signaling networks. Cell 2008 May; 133(4): 666-680.
Bromberg KD, Ma'ayan A, Neves SR, Iyengar R. Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science 2008 May; 320(5878): 903-909.
Ma'ayan A, Jenkins SL, Neves S, Hasseldine A, Grace E, Dubin-Thaler B, Eungdamrong NJ, Weng G, Ram PT, Rice JJ, Kershenbaum A, Stolovitzky GA, Blitzer RD, Iyengar R. Formation of regulatory patterns during signal propagation in a Mammalian cellular network. Science 2005 Aug; 309(5737): 1078-1083.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Iyengar did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.